Search
Close this search box.

Embrace
the evidence.

We have embraced a data-driven approach to the development of the DETOUR™ System.

PTAB with the DETOUR System is clinically proven to be a safe and effective treatment for patients with long complex SFA disease.

The DETOUR2 Study is a prospective, single-arm, multicenter, international clinical investigation to evaluate the safety and effectiveness of the DETOUR System.

CLINICALLY DEMONSTRATED IN PATIENTS WITH UNMET NEEDS:

0 cm
mean
lesion length1
0 %
chronic total occlusion before the DETOUR System1
0 %
of enrolled patients had in-stent-restenosis1
0 %
had previous peripheral intervention1
Clinical evidence demonstrates PTAB using the DETOUR System is a safe and effective treatment option for patients with long complex SFA disease.

DEMONSTRATED EFFICACY

0 %
freedom from
CD-TLR at 2 year3
0 %
freedom from 100%
occlusion at 2 year3
0 %
clinical success*
at 2 year4

DEMONSTRATED SAFETY

0 %
infection rate
at 30 days3
0 %
freedom from major adverse events at 30 days1
0 %
DVT rate at
30 days1

MINIMAL HOSPITAL STAYS

0 DAY
average hospital stay
post-procedure3
*Clinical success is defined as an improvement in limb ischemia with a scale increase of ≥1 according to the Rutherford Classification.

Be one of the first to try PTAB with the DETOUR System

Contact Us:

Contact Us

REFERENCES
  1. Lyden. Percutaneous Bypass for Treatment of Long-Segment Femoropopliteal Disease: 12 Month Results from the DETOUR 2 Trial Volume 75, Issue 6, E337-E338, June 2022
  2. P220021 Summary of Safety and Effectiveness Data (SSED). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm
  3. Lyden et al. Durability of Percutaneous Bypass for Treatment of Femoropopliteal Disease: Two-year Outcomes of the DETOUR-2 Study. VAM 2023
  4. The DETOUR System IFU 117 Rev A
Legal Information:

Disclaimer:

The DETOUR™ System and associated components: ENDOCROSS Device and TORUS Stent Graft System are only available in the United States.

Please contact your Endologix representative for details regarding product availability.

If you are an HCP practicing in the United States:

Prior to use, refer to Instructions for Use for more information concerning Indications, Contraindications, Specific Anatomic Considerations, Warnings, Precautions, and Adverse Events. Rx only.
© Endologix LLC. All rights reserved.